Bone Scan Index as a prognostic imaging biomarker during androgen deprivation therapy

EJNMMI Research

Table 3 Survival analysis demonstrating association between age, PSA, cT, GS and BSIduring ADT

Variable at follow-up	N	Hazard ratio	pvalue
Univariate analysis
Age	146	1.04 (1.004 to 1.07)	0.03
PSA	146	1.0002 (1.00002 to 1.0003)	0.03
TS	131	2.39 (1.41 to 4.04)	0.001
GS	135	1.75 (1.32 to 2.32)	0.0001
BSI	146	1.26 (1.18 to 1.35)	<0.0001
Multivariate analysis
Age	121	1.04 (1.0004 to 1.08)	0.03
PSA	121	1.0006 (1.0003 to 1.0009)	<0.0001
TS	121	2.09 (1.24 to 3.51)	0.006
GS	121	1.70 (1.23 to 2.35)	0.001
Multivariate analysis
Age	121	1.05 (1.01 to 1.09)	0.009
PSA	121	1.0004 (1.00001 to 1.0008)	0.04
TS	121	1.98 (1.21 to 3.24)	0.007
GS	121	1.47 (1.04 to 2.08)	0.03
BSI	121	1.19 (1.09 to 1.29)	<0.0001

PSA, prostate-specific antigen; cT, clinical stage; GS, Gleason score; BSI,Bone Scan Index; ADT, androgen deprivation therapy; N, number of patients.